GI Drugs Flashcards

1
Q

drugs used in acid-peptic diseases

A

Drugs that reduce intragastric acidity

  • Proton Pump Inhibitors
  • H2-Receptor Antagonists
  • Antacids

Drugs that promote mucosal defense

  • Sucralfate
  • Prostaglandin Analogs
  • Bismuth Compounds
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

GERD treatment goals

A
o	Alleviate/eliminate sx
o	Decrease reflux frequency, recurrence & duration
o	Promote injured mucosal healing
o	Prevent complication development
o	Therapy target:
-Increase lower esophageal sphincter (LES) pressure – you need the stomach to empty fast enough so that the acid doesn’t splash back up
-Enhance esophageal acid clearance
-Improve gastric emptying
-Protect esophageal mucosa
-Decrease refluxate acidity 
-Decrease gastric volume
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

GERD treatment phase I

A

o Lifestyle modifications

  • Elevate the head of the bed – laying flat – no gravity to help them
  • Stop smoking (decreases spontaneous esophageal sphincter relaxation) - Nicotine in any way decreases sphincter relaxation
  • Avoid alcohol (increases amplitude of the lower esophageal sphincter, peristaltic waves and frequency of contraction)
  • Avoid tight-fitting clothes

o Dietary changes

  • Avoid irritating foods – different for everyone so you have to talk to the pt about what their trigger foods are
  • Small meals and avoid eating within 3h before sleeping (decrease gastric volume)
  • Weight reduction

o Avoid drugs that may worsen

o Patient-directed therapy with antacids and/or OTC H2-receptor antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

symptoms associated with GERD

A

-Belching
-Difficulty or pain when swallowing (Dysphagia)
-Waterbrash (sudden excess of saliva)
-Chest Pain
-Chronic sore throat
-Laryngitis
-Inflammation of the gums – dentists will sometimes recognize GERD due to these symptoms
-Erosion of the enamel of the teeth
-Chronic irritation in the throat
-Hoarseness in the morning
-A sour taste
-Bad breath
o 10-20% GERD prevalence in Western world

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

GERD factors worsening symptoms

A

o Foods

  • Caminatives (peppermint, spearmint)
  • Chocolate
  • Coffee, cola, tea
  • Fatty meal
  • Garlic Onions
  • Spicy foods
  • Orange/tomato juice

o Medications

  • Anticholinergics
  • Barbiturates
  • Benzodiazepines
  • Caffeine
  • Dihydropyridine calcium channel blockers
  • Dopamine
  • Estrogen – one of the most common symptoms of pregnancy
  • Ethanol
  • Isoproterenol
  • Narcotics
  • Nicotine
  • Nitrates
  • Progesterone
  • Theophylline
  • Alendronate
  • Aspirin
  • Iron
  • NSAIDs
  • Quinidine
  • Potassium Chloride
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

GI tract and pregnancy

A

o When you are pregnant, your whole GI tract slows down!! ¼ of the speed to ensure absorption of the most nutrients as possible
o 3 reasons pregnant women get it: slowed GI, extra estrogen, pressure form baby

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

GERD treatment: phase II

A

o Acid-suppressing therapy
-H2 receptor antagonists
-Proton pump inhibitors (Start if present with more severe sx or with erosive esophagitis)
-Other: Pro-motility agents, sucralfate (rare)
o Maintenance therapy: 70 - 90% will relapse in 1 year after d/c
o Consider long term therapy
-Relapse
-Complications (Barrett’s esophagus, strictures, or hemorrhage)
o Use standard doses unless less-severe disease
o More severe - Higher doses in complicated sx, high-grade erosive esophagitis
o Barrett’s esophagus- normal stratified squamous epithelium replaced by abnormal columar epithelium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Zollinger-Ellison syndrome - treatment goals

A

o Gastrin-secreting tumors
o Locate and possibly reduce gastrinoma
o Surgical options
o Medical management
-PPI , H-2 antagonists are not curative, but limit complications.
o Condition in which there is increased production of gastrin sometimes caused by tumor in pancreas or small intestine
o NSAIDs block COX1 and therefore decrease prostaglandin synthesis – increase risk of ulcers
-Naproxen is worse for ulcers! You could go to a selective NSAID (Celebrex, etc. that are COX2 selective)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

peptic ulcer disease - treatment

A

o Varies depending on etiology, initial or recurrent, complications
o Relieve pain, heal ulcer, prevent recurrence and reduce complications
o Eliminate/reduce irritants
-NSAIDs (If cannot discontinue administer with food or H2-receptor antagonist or PPI)
-Eradicate HP
o PPI’s provide more rapid symptom & faster ulcer healing
o 90% of PU caused by H.Pylori or NSAIDs !!!!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

PUD - treatment

A

o NSAIDs

  • Empirically treat with H2 blocker or PPI
  • If NSAID is discontinued, uncomplicated ulcer heals with H2 blocker, PPI or sucralfate
  • Larger ulcers require PPI or prolonged treatment
  • PPI’s reduce ulcer incidence & complications in pts continuing aspirin or NSAIDs
  • NSAID dose reduction, use acetaminophen or nonacetylated salicylates, relatively selective COX-2 inhibitors (nabumetone, etodolac, meloxicam, celecoxib)

o Prevent rebleeding

  • High dose or continuous intravenous PPI infusion for 3-5 days reduces rebleeding
  • Intragastric pH>6 enhances coagulation and platelet aggregation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Antacid - base 101

A

o NaHCO3 + HCl  CO2 + NaCl
-CO2 is going to cause burping or farting – this is sometimes uncomfortable or embarrassing
o CaCO3 + HCl  CO2 + CaCl
o Al(OH)3 + HCl  H2O + AlCl3
o Mg(OH)2 + HCl  H2O + MgCl2
o Simethicone (antiflatulant)
-Alters elasticity of mucus-coated bubbles, causing them to break
-Used often, but there are limited data to support effectiveness
-80mg po (chewed tablets) QID

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

consequences of PPIs instability

A

o PPIs formulation protects itself from stomach’s acidic pH by enteric coating
o Pantoprazole & Rabeprazole
-Coated tablets → they cannot be crushed
o Omeprazole, Esomeprazole & Lansoprazole
-Coated granules → they can be opened
o Weak antacids or alkaline juices may break the enteric coat
o Unlike antacid, PPI must be absorbed into blood stream first
o Need to take it before the largest meal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

how are PPI’s are administered

A

-administered as inactive prodrugs. To protect the acid-labile prodrug from rapid destruction within the gastric lumen, oral products are formulated for delayed release as acid-resistant, enteric-coated capsules or tablets. After passing through the stomach into the alkaline intestinal lumen, the enteric coatings dissolve and the prodrug is absorbed. For children or patients with dysphagia or enteral feeding tubes, capsules may be opened and the microgranules mixed with apple or orange juice or mixed with soft foods (applesauce). Lansoprazole is also available as a tablet formulation that disintegrates in the mouth, or it may be mixed with water and administered via oral syringe or enteral tube. Omeprazole is also available as a powder formulation (cap or packet) that contains sodium bicarbonate (1100-1680 mg NaHCO3) to protect the naked (non-enteric-coated) drug from acid degradation. When administered on an empty stomach by mouth or enteral tube, this “immediate-release” suspension results in rapid omeprazole absorption (Tmax <30 minutes) and onset of acid inhibition.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

24-hour intragastric acidity - mild to moderate GERD = H2

A

o If you have pt with active ulcer with H pylori or Zolinger Ellison, Barretts esophagus = PPI
o PPis are pretty flat except a little bump at night
o PPIs easily last 24 hrs – so if someone has one large meal and its dinner, then have them take the PPI before dinner and it should last until the next day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

stress related mucosal damage (SRMD)

A

o Stress ulceration 1.5 to 8.5% of ICU patients, but up to 15% of patients not on prophylaxis.
o Ulceration in proximal regions of the stomach within hours of major trauma or serious illness
o Likely due to both:
-impaired mucosal protection (due to poor perfusion, uremic toxins, refluxed bile salts
-Hypersecretion of acid (gastrin stimulation of parietal cells
o Influence of H. Pylori infections?
o Prophylax in pts on tube feeds may increase mortality and HCAP w/o reducing GI bleeding
-DO NOT proph low risk pts
o Prophylaxis should be given to all patients with the following risk factors:
-Coagulopathy (Plts under 50, INR over 1.5, or PTT over 2x control)
-Mechanical vent over 48hrs
-h/o GI bleed in last year
-Traumatic brain/spinal injury
-Burn patients
-Two or more of the following: Sepsis, ICU stay over 1 week, Steroids over 250mg HCT, h/o GI bleed over 6 days
o if pts aren’t high risk, it can actually increase mortality!! DO NOT PROPHYLAX LOW RISK PTS!!!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

helicobacter pylori

A

o 50% of population colonized
-Higher in developing countries
o Approximately 15% of colonized individuals develop clinical manifestation of ulcer
o Eradication decreases reoccurrence risk
o Causes ulcer by direct effects, inflammation & increased gastric acid secretion
o HP is resistant to antibiotic at low pH since their activity & multiplication is limited. The higher the pH, the better the response to antibiotics
o PPIs: can raise the pH to 6 (at high dose)
o H2RA: cannot raise the pH above 4
o Triple drug therapy no longer considered 1st line due to clarithromycin resistence!
o Quadruple therapy x 14 days
-Proton pump inhibitor BID
-Three antibiotics (Clarithromycin & amoxicillin & metronidazole - BID, no bismuth side effects) (Bismuth & metronidazole & tetracycline - QID, bismuth side effects)

17
Q

mucosal protective agents - bismuth

A

o Bismuth subsalicylate (Pepto-Bismol, Kaopectate)
o Bismuth subcitrate potassium (Helidac)
o Coats ulcers & erosions
o Creates protective layer against acid & pepsin.
o Stimulates mucous, prostaglandin & HCO3
o Bismuth subsalicylate reduces stool frequency & liquidity in infectious diarrhea
o Direct antimicrobial effects/binds entertoxins (traveler’s diarrhea)
o Direct antimicrobial activity against H pylori

18
Q

GERD prokinetic agents

A

o Use in patients with known or suspected motility disorders or inpatients who fail high-dose PPI
o Metoclopramide
-Increase lower esophageal sphincter pressure in dose-related manner
-Accelerates gastric emptying
-Some symptomatic improvement
-Side effects & tachyphylaxis limits usefulness

19
Q

constipation

A

Functional definition: > 2 of the following complaints present for at least 12 months when not taking laxatives

  • Straining
  • Incomplete evacuation
  • < 2 BMs in one week

As many as 40% of pts over 65 yo

Factors found to correlate with self-reported constipation
-Age, sex (F>M), total number of drugs taken, abdominal pain, hemorrhoids

20
Q

treatment approach of constipation

A

Dietary and life-style modification
-Fiber(10g): increases stool bulk, stool water retention & stool transit rate through intestine

Correct underlying disease

Discontinue/lower dose of constipation-causing medications

Surgery
-Segment of intestine resected/revised to allow flow of GI contents

21
Q

drug induced constipation

A

o Analgesics
 PG synthesis inhibitors
Opiates***
o Anticholinergics
 Antihistamine
 Antiparkinsonian
 Phenothiazines
 TCAs
o Muscle blockers (D-tubocurarine, succinylcholine
o Polystrene sodium sulfonate
o Antacids containing calcium or Al(OH)3
o Barium sulfate
o Calcium channel blockers
o Clonidine
o Diuretics (non-potassium sparing) – they are drying you out – dehydration causes constipation
o Iron supplements
o Don’t need to memorize this chart  just helps to put everything together
 Docusate combination with senna is NO DIFFERENT than senna alone for frequency and volume of BMs. BUT docusate does soften the stool
 You don’t give docusate alone unless they are pregnant
o The chart for the agents and recommended dose heading: phenolphthalein is no longer available
 Magnesium citrate is what she uses, VERY effective

22
Q

diarrhea treatment

A

– in general, she does not want to stop diarrhea, she wants it to run its course because you are trying to get something bad out of your body
o Nonpharmacologic
 Dietary
• Stop solids X 24hrs and avoid dairy
• Fasting only in osmotic diarrhea
• Feed children with bacterial diarrhea
 Water & Electrolytes
• Volume depletion: Replace to normal body composition
• Parenteral and enteral routes if necessary
• Oral rehydration solutions? Really about getting electrolytes in
o Pharmacologic
 Use Anti-diarrheal Agents
• Mild to Moderate acute diarrhea
• Avoid in bloody diarrhea, high fever, or systemic toxicity
• Stop if diarrhea worsening

23
Q

IBS

A

o Idiopathic chronic relapsing disorder
o Common GI disorder
o Adult prevalence of 10-15%
o Strong female predominance (70-75%)
o Individuals with IBS noted to have elevated 5-HT3 levels
o Symptoms
 abdominal pain and altered bowel habits (diarrhea and/or constipation)

24
Q

IBS initial therapy

A

o Dietary Modification: ALWAYS FIRST LINE
 Regular meal patterns, avoid large meals
 Reduce intake of fate, caffeine, alcohol
 Lactose or gluten intolerance?
• 2 week trial suggested if IBS with diarrhea?
 Reduce intake of gas producing foods
• Beans, onions, celery, carrots, raisins, bananas, apricots, prunes, Brussel sprouts, wheat germ, pretzels, bagels, etc
o Increased physical activity shown to improve symptoms

25
Q

dietary modifications for IBS

A

Eliminate offending items

  • lactose
  • caffeine
  • fatty foods
  • alcohol
  • sorbitol gum
  • large meals
  • food sensitivity
  • gas producing foods

Increase fiber (constipation)

26
Q

IBS treatment if they fail initial tx

A

o Treatment (only if fail initial or affects QoL)
o Constipation: dietary fiber 1 tablespoonful up to TID, if cannot tolerate dietary bran, use psyllium and try to avoid laxatives
o Diarrhea
 Avoidance: caffeine, alcohol, artificial sweeteners (sorbitol, fructose, mannitol), herbal medicines or teas
 Loperamide
 Cholestyramine if diarrhea related to idiopathic bile acid malabsorption or following cholecystectomy
o Pain: Antidepressants: TCA,SSRI
 Avoid TCA if with constipation

27
Q

PTSD from vomiting

A

o Ex) every time you smell Malibu you want to vomit because you remember when you were hungover
o Benzodiazepines: Best therapeutic alternative
 Lorazepam & diazepam dosed before & multiple doses after each treatment with cytotoxic chemotherapy
 Treat the following symptoms:
1. N/V after 1st treatment
2. Nausea after 1st treatment described as “moderate, severe or intolerable”
3. <50yrs old
4. Susceptibility to motion sickness
5. Feeling warm or hot all over after treatment
6. Sweating following treatment
7. Feelings of generalized weakness

28
Q

IBD

A

o Bowel wall infiltrated with lymphocytes, plasma cells, mast cells, macrophages, and neutrophils
o Systemic manifestations have immunologic etiology
o Responsive to immunosuppressive agents
o Ulcerative Colitis (UC)
 Colon/rectum mucosa & submucosa
 Toxic megacolon
 Cancer risk
o Crohn’s disease
 Mouth to anus: common in terminal ileum
 Strictures and fistula
o IBD natural history
 Self-limited
 Mild - Mod with 20% spontaneous improvement
 Small % progress to sev dis
• Cannot expect improvement with severe colitis
 Ulcerative Colitis (UC)
• Remission ~1 yr with medical therapy or ~9 months without
 Crohn’s
• 26 - 42% of patients achieved temporary remission without drugs
• Remission can last up to 2 yrs without drug therapy in mild to moderate disease

29
Q

aminosalicylates

A

-used in IBD
o 5-aminosalicylic acid (5-ASA) = mesalamine
o 80% aqueous unformulated 5-ASA absorbed from small intestine
o Other formulations designed to deliver 5-ASA to distal small bowel or colon (AZO vs. delivery)

30
Q

IBD: anti TNF therapy MOA

A

 Dysregulation of the T helper cell type 1 (TH1) response is present in IBD, especially Crohn’s
 Tumor necrosis factor α (TNF- α ) is the key pro-inflammatory cytokine in the TH1 response
 Binds to soluble TNF- with high affinity, preventing the cytokine from binding to its receptors
 Reduces infiltration of inflammatory cells and TNF- production in inflamed areas of the intestine, and also reduces the proportion of the mononuclear cells able to express TNF-

31
Q

pancreatitis

A

o Acute Pancreatitis (AP)
 Severe pain in the upper abdomen and increased serum concentrations of pancreatic lipase and amylase
o Severe Pancreatitis (SP)
 Local complications such as active fluid collection, pancreatic necrosis, abscess, pseuduocyst, Multi organ failure-including shock, pulmonary insufficiency, metabolic and cardiac complications, and renal failure contributes to poor prognosis
o Chronic Pancreatitis (CP)
 Syndrome of destructive and inflammatory conditions related to long-standing pancreatic injury
 Exocrine & endocrine tissue fibrosis & destruction
 Histological & functional changes are irreversible
 Increased risk of pancreatic cancer

32
Q

adjuncts to pancreatic enzyme therapy

A

o H2RA or PPI
o Help maintain luminal gastric and duodenal pH>4 and enhance lipase activity
 Prevents bile acid precipitation, increasing fatty acid precipitation
 Decrease intragastric volume
o Add to patients with unimproved steatorrhea

33
Q

portal hypertension and cirrhosis

A
o	Varices are essentially shortcuts
o	Ascites
o	Hepatic encephalopathy
o	Portosystemic collaterals
	Gastric or esophageal varices
	Rupture can lead to massive upper GI bleeding
o	Spontaneous bacterial peritonitis
34
Q

cirrhosis treatment

A

o Identify & eliminate cause of cirrhosis
o Asses risk for variceal bleeding & begin pharmacologic prophylaxis, reserve endoscopic therapy for high-risk patients or acute bleeding episodes.
 Variceal obliteration with endoscopic techniques is the recommended treatment of choice in patients with acute bleeding
o Evaluate for clinical signs of ascites and manage with pharmacologic therapy .
 Monitor spontaneous bacterial peritonitis if undergo acute deterioration
o Hepatic encephalopathy
 common complication of cirrhosis
 Requires clinical vigilance and treatment with dietary restriction, elimination of CNS depressants and lower ammonia levels.
o Frequent monitoring for signs of hepatorenal syndrome, pulmonary insufficiency and endocrine dysfunction is necessary.
o Ive never seen a patient survive hepatorenal syndrome

35
Q

portal hypertension and variceal bleeding

A

o Reduction of portal venous pressure and the pressure within the varices
o Resistance to flow through the liver is a fixed process whereas the vasodilatory effects on the splanchnic blood flow are reversible and form the first treatment option
o Management
 Prevent first bleeding episode
 Treat acute variceal hemorrhage
 Prevent rebleeding in patients with previous bleed

36
Q

portal hypertension and variceal bleeding primary prophylaxis

A

o PROPRANOLOL IS DOC!!
o Non-selective Β-adrenergic blockers
 Block the adrenergic dilatory tone of mesenteric arterioles resulting in unopposed α-adrenergic-mediated vasoconstriction, and a decrease in portal inflow and portal pressure
 Reduce by 50% & continued lifelong unless not tolerated
 Propranolol 10mg TID or nadolol 20mg once daily
• Decrease resting HR by 20 to 25%, or heart rate of 55-60bpm, or ADEs
o Nitrates
 Smooth-muscle vasodilatation & reduction in portal pressure
 Isosorbide-5-mononitrate resulted in higher long-term mortality than propranolol in pts >50 yrs
• Nitrates can increase portal blood flow →↑portal pressure by enhancing nitric oxide-mediated vasodilatation of the mesenteric vasculature
 Isosorbide-5-mononitrate 10mg BID and increase to 20mg TID after 1 week
 Use if inadequate response to Beta blocker

37
Q

variceal hemorrhage: somatostatin and octreotide

A

o ↓ splanchnic blood flow→↓ portal blood flow and↓ portal and variceal pressures
o Somatostatin 250mcg/h or octreotide IV bolus of 50-100mcg and is followed by CI of 25 up to 50mcg/h for 3-5 days
o Well tolerated, hypo- or hyperglycemia and cardiac conduction abnormalities
o Endoscopy employing EBL or EIS is the primary therapeutic tool
o If standard therapy fails (2 failed endoscopic procedures), a salvage procedure such as balloon tamponade, TIPS, or surgical shunting
o Transjugular intrahepatic portosystemic shunt
o Esophageal Band Ligation
o Endoscopic injection sclerosis

38
Q

asciteds treatment

A

o Physical exam or radiographic studies
o Paracentesis
 Cell count with differential and a serum-ascites albumin gradient (SAG)
• >1.1 g/dL=portal hypertension with 97% accuracy
o Abstain from Alcohol
 Sodium restriction to 2,000mg/d
 Diuretic Therapy
 Spironolactone 100mg and furosemide 40mg QAM with goal of 0.5kg max daily weight loss (up to 400mg/160mg)
 Ratio maintains normo-kalemia
 Perform paracentesis if tense ascites present 1st
 Discontinue: encephalopathy, severe hyponatremia, renal insufficiency (Scr >2mg/dL)

39
Q

hepatic encephalopathy tx

A

o Limit dietary protein
 Acute: withhold or ≤20g/d
 Increase every 3 - 5 days up to 0.8 to 1 g/kg/d; Chronic limit to 40g/d
o Inhibit urease-producing bacteria
 Neomycin 2 to 8gm/daily in divided doses
• Efficacy same as lactulose but more risk of irreversible ototoxicity and nephrotoxicity
 Metronidazole: limited due to GI SEs
o Others
 Replacing urease-producing bacteria in the colon with non-urease producing strains
• Lactobacillus acidophilus and Enterococcus faecium
• Elimination of H.pylori
 Enhancing ammonia removal by stimulating detoxification by supporting alternative metabolic pathways
• L-ornithine L-aspartate (OA) enhances ureagenesis and reduces ammonia concentration
• Zinc: cofactor for ammonia metabolism
o Mild HE Zinc Sulfate 600mg/d X 3 months=increased urea formation, lower ammonia levels, along with improved psychomimetic test scores
o Recommended for long-term management in zinc deficiency